Fischer Medical Ventures Limited has informed the Exchange regarding a revised press release dated July 10, 2025, titled "Fischer Medical Ventures Ltd s public-private partnership with the City of Jember, Indonesia, to support tuberculosis eradication through AI-powered portable X-ray systems".
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 5.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fischer Medical Ventures Ltd (FMV) has announced a public-private partnership with the City of Jember, Indonesia, to deploy portable, AI-enabled digital X-ray systems for tuberculosis detection and treatment. The program aims to make Jember TB-free by 2026 and supports Indonesia's national goal of eradicating TB by 2030. The estimated program value is over USD 10 million, with phased implementation planned over 2 years. The company will supply its handheld X-ray units (under 3kg) with built-in AI algorithms for rapid TB diagnosis, along with training programs and a 'Trace, Test, Track' solution. The initiative marks FMV's strategic entry into Indonesia's healthcare market of 280 million people, with future expansion to other Indonesian cities anticipated.
This is a significant international expansion that positions FMV in a large, underserved healthcare market and could open doors to long-term government procurement contracts. While the USD 10 million program value is meaningful, the deal's true value may lie in brand building and future collaborations rather than immediate earnings impact. Shareholders should view this as a strategic growth signal rather than a short-term revenue catalyst.